Drugs / GZ21T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06888362 | Aug 2024 → Mar 2025 | actinic keratosis | Genzada Pharmaceuticals USA, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GZ21T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06888362 ↗ |
| Route | Topical | “after topical administration of single ascending doses of GZ21T in healthy volunteers.” NCT06888362 ↗ |